Mood Disorders News

A meta-analysis of neuroimaging studies indicated inconsistencies across results of neuroimaging experiments in unipolar depression and replication issues of neuroimaging meta-analyses.

Otsuka and Lundbeck recently announced the FDA accepted a supplemental New Drug Application to expand labeling of Abilify Maintena for maintenance treatment of bipolar I disorder in adults.

Individuals with treatment-resistant major depressive disorder who participated in Sudarshan Kriya yoga exhibited significant improvement in depression and anxiety scores, compared with peers who did not participate in yoga.

MRI analysis indicated sex-specific associations between gray matter volume and future substance abuse in adolescents with bipolar disorder.

Phase 2 study findings from Cerecor indicated CERC-301, an oral, N-methyl D-aspartate receptor subtype 2B selective antagonist, was not significantly effective as an adjunctive treatment for treatment-resistant major depressive disorder.

Men who endorsed masculine norms such as self-reliance, power over women and playboy lifestyle were more likely to report negative mental health outcomes, according to recent findings.

NeuroStar recently announced the launch of a large depression outcomes registry for individuals treated with its transcranial magnetic stimulation therapy.

Celebrex, a COX-2 inhibitor indicated for arthritis, significantly improved antidepressant efficacy among individuals with treatment-resistant bipolar depression, according to findings presented at the International Congress on Psychiatry and the Neurosciences.

Analysis of nationally representative data indicated a significant increase in prevalence of major depressive episodes within the last year among adolescents and young adults.

Fewer daylight hours between sunrise and sunset was associated with poorer mental health, according to recent findings.